sponsored
PatientsVille.com Logo

PatientsVille

Drospirenone Medical Research Studies

Up-to-date List of Drospirenone Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Drospirenone Medical Research Studies

Rank Status Study
1 Recruiting Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants
Conditions: Polycystic Ovarian Syndrome;   Hyperandrogenism;   Menstrual Irregularities
Interventions: Drug: 20 mcg ethinylestradiol /3 mg Drospirenone;   Drug: 20 mcg ethinylestradiol/3 mg Drospirenone and Selmevit;   Drug: 30 mcg ethinylestradiol/3 mg Drospirenone;   Drug: 30 mcg ethinylestradiol/3 mg Drospirenone and Selmevit;   Drug: 35 mcg ethinylestradiol/2 mg cyproterone;   Drug: 35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
Outcome Measures: Change from Baseline in Activated recalcification time;   Change from Baseline in Activated partial thromboplastin time;   Change from Baseline in Prothrombin time;   Change from Baseline in International normalized ratio;   Change from Baseline in D-dimer concentration;   Change from Baseline in Fibrinogen concentration;   Change from Baseline in Soluble fibrin-monomer complexes concentration;   Change from Baseline in Platelet aggregation;   Change from Baseline in Antithrombin III activity;   Change from Baseline in Reserve plasminogen index;   Change from Baseline in Erythrocyte Lipoperoxidation products, extractable in heptane and isopropanol;   Change from Baseline in Malondialdehyde Concentration in Erythrocytes;   Change from Baseline in Glutathion-S-transferase Activity in Erythrocytes;   Change from Baseline in Superoxide dismutase Activity in Erythrocytes;   Vitamin A and E plasma concentration;   Frequency of adverse effects;   Subjective tolerability of contraceptives
2 Recruiting Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea
Condition: Dysmenorrhea
Intervention: Drug: EE20/DRSP(BAY86-5300)
Outcome Measures: Number of days with dysmenorrheic pain over 140 days of evaluation period;   Change in Dysmenorrhea score from baseline to period of withdrawal bleeding;   Change of severity of pain Description;   Number of days with at least moderate dysmenorrheic pain over 140 days of evaluation period;   Number of days with rescue medicine used for relief of dysmenorrhea or pelvic pain over 140 days of evaluation period;   Number of days with interference of dysmenorrheic pain with daily activity over 140 days of evaluation period;   Endometrial thickness;   Number of days with bleeding and spotting over treatment phase
3 Recruiting INAS-FOCUS (International Active Surveillance Study - Folate in Oral Contraceptives Utilization Study)
Condition: Contraception
Intervention:
Outcome Measures: Cardiovascular events;   Cancer
4 Unknown  Effects of Drospirenone-ethinylestradiol and/or NOMAC-valerate Estradiol on Cardiovascular Risk in Women With Polycystic Ovary Syndrome
Condition: Polycystic Ovary Syndrome
Interventions: Drug: Zoely;   Drug: Yasmin
Outcome Measure: cardiovascular risk
5 Recruiting Comparison of Levonorgestrel Intrauterine System, Copper T Intrauterine Device and Oral Contraceptives on Life Quality
Condition: Contraceptive Methods Comparison
Interventions: Drug: YASMIN® (Drospirenone/Ethinyl Estradiol);   Device: The Copper-T is an intrauterine device (IUD);   Device: levonorgestrel-releasing system
Outcome Measures: Lipid profile (HDL,VLDL,IDL,LDL,Lp(a),VLDL)Lng-ius users, Copper-iud users and combined oral contraceptive users (composite measurement);   coagulation parameters(composite measurement)
6 Recruiting Low Dose OC Therapy in Women With Polycystic Ovary Syndrome (PCOS): Impact of BMI on Hyperandrogenism
Condition: Polycystic Ovary Syndrome
Intervention: Drug: 3 mg DRSP/20 μg EE
Outcome Measures: biochemical assessment of hyperandrogenism;   Cardiometabolic measures;   anthropometric measures;   biochemical indicators of B-vitamin status;   menstrual cycle regulation
7 Unknown  Effects of Estradiol on Menopausal Breast
Condition: Hormone Replacement Therapy
Intervention: Drug: Angemin vs Activelle
Outcome Measures: Mammographic breast density - classified according to digitized data-based quantification of breast density.;   Effects on serum levels of Oestradiol etc.
8 Recruiting The Influence of Peripheral Androgen Conversion at Women Adult Acne
Conditions: Acne;   Quality of Life
Interventions: Drug: treatment azelaic acid (azelan);   Drug: dorspirenone/ethynil estradiol
Outcome Measures: Clinical evaluation of the treatment group;   Photographic study of the treatment group
9 Recruiting Comparison Between Oral Contraceptive Pills and Calcium Supplements in Treatment of Premenstrual Syndrome
Condition: Premenstrual Syndrome
Interventions: Drug: Yasmin;   Dietary Supplement: Calver;   Drug: Placebo
Outcome Measure: Improvement of premenstrual symptoms.
10 Unknown  Metformin and Oral Contraceptives in PCOS
Condition: Polycystic Ovary Syndrome
Interventions: Drug: Metformin;   Drug: Yasmin
Outcome Measures: Changes in fasting insulin and area under the curve for insulin (2 hours);   Changes in BMI, WHR, LH, FSH, total and free testosterone, fasting blood glucose, fasting C-peptide, urine-cortisol secretion, body composition, number of hypoglycaemic cases, AUC for insulin, glucose and C-peptide during OGTT (2 and 5 ho
11 Recruiting YAZ Post-marketing Surveillance in Japan
Condition: Dysmenorrhea
Intervention: Drug: EE20/DRSP(YAZ, BAY86-5300)
Outcome Measures: Incidence of adverse drug reactions and sever adverse events;   Change from baseline in severity of dysmenorrhea at 6th cycles (28 days per cycle);   Incidence of adverse events;   Unpleasant physical symptoms collection;   Unpleasant psychological symptoms collection;   Analgesic drug for dysmenorrhea;   QOL survey using Short-Form 36-Item Health Survey (SF-36)

These studies may lead to new treatments and are adding insight into Drospirenone etiology and treatment.

A major focus of Drospirenone research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Drospirenone